Academia Employers Health System Payers Providers

Center on Health Equity and Access Clinical Health Care Cost Health Care Delivery Insurance Policy Technology Value-Based Care

All Coverage Event Coverage Interviews News

AJMC Journals Anniversary Author Forms Authors Nominate a Rising Leader Submit a Manuscript

A Review of the Treatment for Multiple Myeloma

home / peer-exchange / review-of-treatment-for-multiple-myeloma

Individualizing Therapy for Multiple Myeloma Patients

EP. 1: Individualizing Therapy for Multiple Myeloma Patients

Watch

Factoring Age Into Frontline Therapy for MM

EP. 2: Factoring Age Into Frontline Therapy for MM

Watch

Cost Considerations of Multidrug Regimens in MM

EP. 3: Cost Considerations of Multidrug Regimens in MM

Watch

Achieving the Best Outcomes for Patients With MM

EP. 4: Achieving the Best Outcomes for Patients With MM

Watch

NCCN Guidelines for Newly Diagnosed MM

EP. 5: NCCN Guidelines for Newly Diagnosed MM

Watch

Considerations for Transplant-Ineligible Patients

EP. 6: Considerations for Transplant-Ineligible Patients

Watch

Practical Implications of the MAIA Study for MM

EP. 7: Practical Implications of the MAIA Study for MM

Watch

Clinical Significance of MRD Testing in MM

EP. 8: Clinical Significance of MRD Testing in MM

Watch

Daratumumab in the Treatment Landscape for MM

EP. 9: Daratumumab in the Treatment Landscape for MM

Watch

What Is the Cost of Recurrence in Multiple Myeloma?

EP. 10: What Is the Cost of Recurrence in Multiple Myeloma?

Watch

$Initiating Treatment in Relapsed-Refractory MM$

EP. 11: Initiating Treatment in Relapsed-Refractory MM

Watch

$Dosing Strategies in Relapsed-Refractory MM$

EP. 12: Dosing Strategies in Relapsed-Refractory MM

Watch

How Real-World Data Can Address Problems in MM

EP. 13: How Real-World Data Can Address Problems in MM

Watch

Backbone Therapy in Newly Diagnosed Multiple Myeloma

EP. 14: Backbone Therapy in Newly Diagnosed Multiple Myeloma

Watch

Strategy for Up-front Therapy of Multiple Myeloma

EP. 15: Strategy for Up-front Therapy of Multiple Myeloma

Watch

Impact of Maintenance Therapy in Multiple Myeloma

EP. 16: Impact of Maintenance Therapy in Multiple Myeloma

Watch

FORTE Trial: Transplant in Patients with Multiple Myeloma

EP. 17: FORTE Trial: Transplant in Patients with Multiple Myeloma

Watch

Payer Perspective: Transplant and Toxicities in MM Therapy

EP. 18: Payer Perspective: Transplant and Toxicities in MM Therapy

Watch

Long-term Data on Improving OS for Patients With MM

EP. 19: Long-term Data on Improving OS for Patients With MM

Watch

Using MRD Negativity to Stop Maintenance Therapy in MM

EP. 20: Using MRD Negativity to Stop Maintenance Therapy in MM

Watch

MAIA Trial: Transplant-Ineligible Patients With MM

EP. 21: MAIA Trial: Transplant-Ineligible Patients With MM

Watch

Entering a 4-Drug Regimen for Multiple Myeloma Treatment

EP. 22: Entering a 4-Drug Regimen for Multiple Myeloma Treatment

Watch

The Impact of OCM in the Treatment of Multiple Myeloma

EP. 23: The Impact of OCM in the Treatment of Multiple Myeloma

Watch

OCM Ensures Better Outcomes and Automatic Cost Savings in Multiple Myeloma

EP. 24: OCM Ensures Better Outcomes and Automatic Cost Savings in Multiple Myeloma

Watch

Reimbursement of Subcutaneous Versus IV Dosing in Multiple Myeloma

EP. 25: Reimbursement of Subcutaneous Versus IV Dosing in Multiple Myeloma

Watch

$Treatment Options in Relapsed/Refractory Multiple Myeloma$

EP. 26: Treatment Options in Relapsed/Refractory Multiple Myeloma

Watch

Patient Cost Implications in Multiple Myeloma Treatment

EP. 27: Patient Cost Implications in Multiple Myeloma Treatment

Watch

Managing Discrepancies in NCCN and Payer Guidelines in Multiple Myeloma

EP. 28: Managing Discrepancies in NCCN and Payer Guidelines in Multiple Myeloma

Watch

Biochemical Versus Symptomatic Relapse Treatment Choices in MM

EP. 29: Biochemical Versus Symptomatic Relapse Treatment Choices in MM

Watch

Final Thoughts on Approach to Multiple Myeloma Treatment

EP. 30: Final Thoughts on Approach to Multiple Myeloma Treatment

Watch

Editorial Staff

Editorial Boards

Do Not Sell My Information

Terms & Conditions

Contact Info

2 Clarke Drive
Cranbury, NJ 08512

© 2023 MJH Life Sciences
AJMC®
All rights reserved.